Literature DB >> 19921439

Points to consider when establishing drug product specifications for parenteral microspheres.

Rajesh Kumar1, Michael J Palmieri.   

Abstract

Drug product specifications are a critical element of a good control strategy. Parenteral microsphere products are complex dosage forms, requiring careful development of test methods and acceptance criteria for the specifications. In particular, the in vitro release test method and acceptance criteria require rigorous scientific consideration and should be developed with an eye toward understanding the mechanisms of drug release. The final specifications need to ensure the safety, identity, strength, performance, and quality of the drug product at release and during storage through the end of its shelf-life. The specification limits are typically established based upon regulatory guidance, available data from the manufacturing process (process capability), from non-clinical, clinical, and stability studies.

Mesh:

Substances:

Year:  2009        PMID: 19921439      PMCID: PMC2811640          DOI: 10.1208/s12248-009-9156-6

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  9 in total

1.  Sterility assurance of microspheres.

Authors:  H Toguchi
Journal:  J Control Release       Date:  1999-11-01       Impact factor: 9.776

2.  Draft guidance for industry; container and closure integrity testing in lieu of sterility testing as a component of the stability protocol for sterile products; availability--FDA. Notice.

Authors: 
Journal:  Fed Regist       Date:  1998-01-28

3.  International Conference on Harmonisation; guidance on Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Notice.

Authors: 
Journal:  Fed Regist       Date:  2000-12-29

Review 4.  Manufacturing techniques and excipients used during the design of biodegradable polymer-based microspheres containing therapeutic peptide/protein for parenteral controlled drug delivery.

Authors:  S Tamilvanan; R Venkatesh Babu; K Kannan; S K Basu; B Sa
Journal:  PDA J Pharm Sci Technol       Date:  2008 Mar-Apr

5.  In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting.

Authors:  Marilyn Martinez; Michael Rathbone; Diane Burgess; Mai Huynh
Journal:  J Control Release       Date:  2008-04-18       Impact factor: 9.776

6.  Formulation design and development of parenteral suspensions.

Authors:  M J Akers; A L Fites; R L Robison
Journal:  J Parenter Sci Technol       Date:  1987 May-Jun

Review 7.  Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties.

Authors:  R Jalil; J R Nixon
Journal:  J Microencapsul       Date:  1990 Jul-Sep       Impact factor: 3.142

8.  Ultrasound-induced degradation of PLA and PLGA during microsphere processing: influence of formulation variables.

Authors:  G Reich
Journal:  Eur J Pharm Biopharm       Date:  1998-03       Impact factor: 5.571

Review 9.  Methods to assess in vitro drug release from injectable polymeric particulate systems.

Authors:  Susan S D'Souza; Patrick P DeLuca
Journal:  Pharm Res       Date:  2006-01-13       Impact factor: 4.580

  9 in total
  7 in total

1.  One-step production of protein-loaded PLGA microparticles via spray drying using 3-fluid nozzle.

Authors:  Feng Wan; Morten Jonas Maltesen; Sune Klint Andersen; Simon Bjerregaard; Camilla Foged; Jukka Rantanen; Mingshi Yang
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

2.  Injectability evaluation: an open issue.

Authors:  Francesco Cilurzo; Francesca Selmin; Paola Minghetti; Marco Adami; Elisa Bertoni; Sara Lauria; Luisa Montanari
Journal:  AAPS PharmSciTech       Date:  2011-05-07       Impact factor: 3.246

Review 3.  Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.

Authors:  Jie Shen; Diane J Burgess
Journal:  J Pharm Pharmacol       Date:  2012-03-08       Impact factor: 3.765

4.  Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study.

Authors:  Philip G Conaghan; David J Hunter; Stanley B Cohen; Virginia B Kraus; Francis Berenbaum; Jay R Lieberman; Deryk G Jones; Andrew I Spitzer; David S Jevsevar; Nathaniel P Katz; Diane J Burgess; Joelle Lufkin; James R Johnson; Neil Bodick
Journal:  J Bone Joint Surg Am       Date:  2018-04-18       Impact factor: 5.284

5.  Key Factor Study for Generic Long-Acting PLGA Microspheres Based on a Reverse Engineering of Vivitrol®.

Authors:  Yabing Hua; Zengming Wang; Dan Wang; Xiaoming Lin; Boshi Liu; Hui Zhang; Jing Gao; Aiping Zheng
Journal:  Molecules       Date:  2021-02-25       Impact factor: 4.411

Review 6.  Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review.

Authors:  Yabing Hua; Yuhuai Su; Hui Zhang; Nan Liu; Zengming Wang; Xiang Gao; Jing Gao; Aiping Zheng
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

7.  Poly(l-Lactic Acid)-co-poly(Butylene Adipate) New Block Copolymers for the Preparation of Drug-Loaded Long Acting Injectable Microparticles.

Authors:  Vasiliki Karava; Aggeliki Siamidi; Marilena Vlachou; Evi Christodoulou; Nikolaos D Bikiaris; Alexandra Zamboulis; Margaritis Kostoglou; Eleni Gounari; Panagiotis Barmpalexis
Journal:  Pharmaceutics       Date:  2021-06-23       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.